She pointed to several other trials of methotrexate in both hand and knee OA that showed little to no benefit, and that in ...

The recent run of successful equity block trades continued on Wednesday evening, with trades in cement maker Heidelberg ...

Former head of bond syndicate might just be what Bank of America needs to achieve its goal — a consistent place among the top ...

Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...